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Abstract
Background: Snake envenomation is a serious public health threat in the rural areas of Asian and African countries. To date,
the only proven treatment for snake envenomation is antivenom therapy. Cross-neutralization of heterologous venoms by
antivenom raised against venoms of closely related species has been reported. The present study examined the cross
neutralizing potential of a newly developed polyvalent antivenom, termed Neuro Polyvalent Snake Antivenom (NPAV).
NPAV was produced by immunization against 4 Thai elapid venoms.
Principal Findings: In vitro neutralization study using mice showed that NPAV was able to neutralize effectively the lethality
of venoms of most common Asiatic cobras (Naja spp.), Ophiophagus hannah and kraits (Bungarus spp.) from Southeast Asia,
but only moderately to weakly effective against venoms of Naja from India subcontinent and Africa. Studies with several
venoms showed that the in vivo neutralization potency of the NPAV was comparable to the in vitro neutralization potency.
NPAV could also fully protect against N. sputatrix venom-induced cardio-respiratory depressant and neuromuscular blocking
effects in anesthetized rats, demonstrating that the NPAV could neutralize most of the major lethal toxins in the Naja
venom.
Conclusions/Significance: The newly developed polyvalent antivenom NPAV may find potential application in the
treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand. Nevertheless, the
applicability of NPAV in the treatment of cobra and krait envenomations in Southeast Asian victims needs to be confirmed
by clinical trials. The cross-neutralization results may contribute to the design of broad-spectrum polyvalent antivenom.
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Introduction
The global figure of snake envenoming cases has been estimated
to be greater than 1.8 million annually, with an annual death toll
of more than 90,000. Most of the snake envenoming cases occurs
in South Asia and Southeast Asia (estimated 720,000 cases, 53,000
fatality), followed by Africa (estimated 420,000 cases, 32,000
fatality) [1], and the main biting species are snakes from the
Elapidae and Viperidae families. Among members of the Elapidae
family, the cobras and kraits are the main causes of snake
envenoming [2,3]. There are about 34 species of cobras belonging
to 7 genera (Aspidelaps, Boulengerina, Hemachatus, Naja, Ophiophagus,
Pseudohaje and Walterinnesia). The genus Naja distributed extensively
across large regions of the Africa (13 species) and Asia (12 species)
[4]. Ophiophagus hannah or commonly known as the king cobra, is
the only member of the Ophiophagus genus and is found only in
Asia. Bungarus (the kraits), are represented by 12 species and their
distribution is confined to the Indian subcontinent, Southeast Asia,
as well as Southern China and Taiwan [4]. Cobra and krait
envenomations are generally characterized by neurotoxic enven-
oming [5].
Antivenom therapy is the only effective treatment for snake
envenomation. Monovalent antivenoms are raised with venom
from one particular species and hence generally only effective in
the treatment of envenomation caused by the particular species.
Because of the difficulties in accurate diagnosis of the biting
species, polyvalent antivenoms that offer paraspecific protection
against several venomous snake bites have also been developed
and become commercially available. It has been argued that
monovalent antivenoms are generally more effective than polyva-
lent antivenoms, though this has not been firmly established. At
present, several types of polyvalent antivenoms against Afro-Asian
venomous snakes are available in the market, produced mainly by
Asian or African commercial pharmaceutical firms or government
institutions [5,6]. There is, however, a lack of rigorous evaluation
of the paraspecific protective actions of these commercially
available polyvalent antivenoms. Recently, Thai Red Cross
Society produced a new polyvalent antivenom that offers
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protection against neurotoxic envenomations by elapids in Thai-
land. This polyvalent antivenom, termed Neuro Polyvalent Snake
Antivenom (abbreviated as NPAV) is raised against venoms of four
medically important cobras and kraits in Thailand, i.e. Naja
kaouthia (Thai monocellate cobra), Ophiophagus hannah (king cobra),
Bungarus candidus (Malayan krait) and Bungarus fasciatus (banded
krait). In this paper, we report evaluation of the cross-neutralizing
potential of NPAV against heterologous venoms of common Afro-
Asian cobras (Naja spp. and Ophiophagus hannah) and Asian kraits
(Bungarus spp.) We also compared the efficacy of the polyvalent
antivenom versus the relevant monovalent antivenom. The results
will provide preliminary information as to whether the polyvalent
antivenom could find therapeutic application for cobra and krait
envenomations outside of Thailand, as well as contribute to the
design of a broad-spectrum, Pan-Asian polyvalent antivenom [7].
Materials and Methods
Venoms and antivenoms
Venoms of Naja sputatrix, Naja siamensis, Naja kaouthia (Thailand),
Naja philippinensis, Naja oxiana, Naja atra, Naja naja (Sri Lanka, sample
1), Naja naja (India, sample 1 and 2), Naja melanoneuca, Naja nigricollis,
Naja nubiae, Naja katiensis, Naja haje, Bungarus multicinctus and Bungarus
caeruleus were purchased from Latoxan (Valence, France). Venoms
of Naja sumatrana, Naja kaouthia (Malaysia), Ophiophagus hannah,
Bungarus candidus, Bungarus fasciatus and Bungarus flaviceps were
pooled samples obtained from several adult individuals captured in
Malaysia whilst Naja naja (Sri Lanka sample 2) was a pooled sample
obtained from several adult individuals captured in Sri Lanka.
After extraction, the venoms were instantly lyophilized. Two
antivenoms were studied: (a) Neuro Polyvalent Snake Antivenom
(NPAV) (Lyophilised; Batch no. 0030208; Exp. Date April 21st,
2013), a purified F(ab9)2 obtained from serum of equines
hyperimmunized against a mixture of four venoms: Naja kaouthia
(Thai monocellate cobra), Ophiophagus hannah (king cobra), Bungarus
candidus (Malayan krait) and Bungarus fasciatus (banded krait); (b)
Naja kaouthia monovalent antivenom (NKMAV) (Full name: Cobra
antivenin; Lyophilised; Batch no. 0090406; Exp. Date August
31st, 2014), a purified F(ab9)2 obtained from serum of equines
hyperimmunized specifically against the venom of Thai N. kaouthia.
Both of these antivenoms are produced by Queen Saovabha
Memorial Institute (QSMI), the Thai Red Cross Society from
Bangkok, Thailand. For neutralization studies, both antivenoms
were reconstituted in the same manner: 10 mL of normal saline
was added to 1 vial of the freeze-dried antivenom. According to
the attached fact sheet, 1 mL of the NPAV antivenom is able to
neutralize the following amount of snake venoms: 0.6 mg each of
N. kaouthia and B. fasciatus venoms, 0.4 mg of B. candidus and
0.8 mg of O. hannah venoms; while 1 mL of the NKMAV can
neutralize 0.6 mg of N. kaouthia venom.
Animals
Albino mice (ICR strain, 20–25 g) and male Sprague Dawley
rats (250–300 g) were supplied by the Laboratory Animal Centre,
Faculty of Medicine, University of Malaya. The animals were
handled according to the guidelines given by CIOMS on animal
experimentation [8]. All experiments involving animals were
approved by the Animal Care and Use Committee (ACUC) of the
University of Malaya (Ethical clearance letter No. PM/03/03/
2010/FSY(R)).
Determination of protein content
Protein content was determined by Bradford method [9]. All
measurements were performed in triplicate. Bovine serum
albumin (Sigma, USA) was use to generate a standard curve.
Chromatographic and electrophoretic profiling of the
antivenom
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was
conducted according to the method of Studier [10], using the
Bio-Rad broad-range prestained SDS-PAGE standards (6.5–
200 kDa) and 15 mL of each antivenom sample (3 mg/mL) was
loaded in the gel (12.5%). High performance gel filtration
chromatography of the reconstituted antivenom (100 mL,
10 mg/mL) was performed using a Superdex 200 HR 10/30,
13 mm SEC 106300 mm (GE Healthcare, Sweden). Elution
buffer was 100 mM sodium phosphate, 0.15 M NaCl, pH 7.4 at a
flow rate of 0.75 mL/min. Protein was monitored by absorbance
measurement at 280 nm. The column was calibrated using the
following protein standards obtained from Bio-Rad (BIO-RAD
Gel filtration Standard): thyroglobulin (670 kDa), c-globulin
(158 kDa), ovalbumin (44 kDa) and myoglobin (17 kDa).
Determination of venom lethality
The median lethal dose, LD50, of the venom was determined by
intravenous or intramuscular injection into ICR mice (20–25 g,
n = 4). The survival ratio was recorded after 48 h to determine the
LD50.
In vitro neutralization of lethality of venoms
In vitro neutralization of lethality was conducted as described by
Ramos-Cerrillo et al. [11]. Briefly, a challenge dose of the venom
in 50 mL saline was pre-incubated at 37uC for 30 min with various
dilutions of the reconstituted antivenom (NPAV or NKMAV) in
normal saline, to give a total volume of 250 mL. The mixture was
subsequently centrifuged at 100006 g before being injected into
the caudal vein of the mice. The number of survival after 48 h was
recorded. Generally, the challenge dose used was 5 LD50.
However, if 200 mL of the reconstituted antivenom (maximum
permitted volume to inject into the mouse) failed to give full
protection of the mice, a lower challenge dose of 2.5 LD50 was
Author Summary
Snake envenomation is a serious public health threat in
the rural areas of Asia and Africa. To date, the only proven
treatment for snake envenomation is antivenom therapy.
Owing to the difficulties in the diagnosis of the biting
species, there is a need to develop polyvalent antivenoms
that could cross-neutralize venoms of medically important
venomous snakes in the various regions. Recently, Thai
Red Cross Society from Thailand has developed a new
polyvalent antivenom for treatment of cobra and krait
venoms. The polyvalent antivenom, termed ‘‘Neuro Poly-
valent Snake Antivenom (NPAV),’’ is raised against venoms
of two Thai cobras and two Thai kraits. Our results
indicated that the polyvalent antivenom can effectively
neutralize venoms from many Southeast Asian cobras,
kraits and king cobra but is less effective against Indian
cobra venoms. Studies using anesthetized rats showed
that NPAV can effectively protect against cobra venom-
induced cardio-respiratory depressant and neuromuscular
blocking effects, confirming that the antivenom can
effectively neutralize the major lethal toxins of common
cobra venoms. This new antivenom may find potential
application in the treatment of elapid bites in Southeast
Asia, especially Malaysia, a neighboring nation of Thailand.
Cross Neutralization of Cobra Venoms
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used instead. The antivenom was considered ineffective when
none of the animals injected with the pre-incubated mixture
(containing 2.5 LD50 challenge venom in 50 mL saline and 200 mL
of the undiluted reconstituted antivenom) survived. Neutralizing
potency of the antivenom was expressed as ED50 (the amount of
reconstituted antivenom in mL or the ratio of mg venom/mL
reconstituted antivenom that gives 50% survival of the animals
tested) as well as in term of ‘neutralization potency’ (P, the amount
of venom that is completely neutralized by a unit volume of
antivenom) calculated according to Morais et al. [12].
In vivo neutralization of lethality of venom
This was carried out by intramuscular injection of 5 LD50 or 2.5
LD50 of the venom into mice (n = 4) followed by intravenous
injection of 200 mL of appropriately diluted reconstituted anti-
venom, 10 min later. The number of survival after 48 h was
recorded.
Protective actions of the antivenom against N. sputatrix
venom-induced cardiovascular depressant and
neuromuscular blocking effects in anesthetized rats
The study was conducted on three groups of rats (n = 3, 250–
300 g) anesthetized with intraperitoneal injection of urethane
(1.4 g/kg, i.p.) to the point of loss of the eyelid reflex and the pedal
withdrawal reflex on painful stimuli. The anesthetized animals
were surgically prepared for the simultaneous measurement of
blood pressure, heart rate, respiratory rate and muscle twitch
tension. Data collection and analysis were conducted using
PowerLab 4/30 data Acquisition system equipped with LabChart
software (AD Instruments, Australia). Rats in group 1 (termed
‘saline/-’ group) were injected with 50 mL saline intramuscularly at
0 min and served as control; Rats in group 2 (termed ‘NsV/-’
group) were injected with 6 mg/kg N. sputatrix venom (dissolved in
50 mL saline) intramuscularly; and rats in group 3 (termed ‘NsV/
NPAV’ group) were injected with the same dose of venom
intramuscularly followed by intravenous administration of 3 mL of
the reconstituted NPAV (1 mL each at 10 min, 30 min and
50 min post-injection of the venom). The volume of antivenom
administered and the time points were chosen to ensure no
disturbance of the blood pressure, heart rate and respiratory rate
occurred.
Statistical analysis
LD50 of the venoms and ED50 of antivenoms are expressed as
means with 95% confidence intervals (C.I.). LD50, ED50 (median
effective dose) and the 95% confidence intervals (C.I.) were
calculated using the probit analysis method of Finney [13] with the
BioStat 2009 analysis software (AnalystSoft Inc.). The statistical
analysis for pharmacological study was conducted using SPSS.
The data (expressed as mean 6 S.D.) were analyzed using one-
way ANOVA, with Tukey’s post hoc multiple-comparison test,
with P,0.05 as significant.
Results
Composition of the antivenoms
The protein contents of reconstituted NPAV and NKMAV
were 20.3 mg/mL and 12.5 mg/mL, respectively. The SDS-
PAGE patterns of NPAV (Neuro Polyvalent Snake Antivenom)
and NKMAV (Naja kaouthia monovalent antivenom) indicated that
there was no distinct band of high or low molecular weight
proteins (Fig. 1). The same was also observed in the gel-filtration
chromatographic profiles of the two antivenoms (Fig. 2). Based on
‘area-under-the-curve’ comparison, the quantity of F(ab9)2 in both
these antivenoms were comparable (91–96%) whilst the quantity
of respective dimers and low molecular weight proteins in
NKMAV were slightly higher than those in NPAV (Figure 2).
No high molecular weight aggregates were detected in both of
these antivenoms.
In vitro neutralization of venom lethal effects by the
antivenoms
The results of the in vitro neutralization of venom lethality by the
NPAV and the monovalent N. kaouthia antivenom (only for selected
venoms) are shown in Table 1 and 2, respectively. The results
showed that NPAV was able to confer protection/cross-protection
against the venoms of all krait as well as almost all the Afro-Asian
cobra venoms examined (except for the African spitting cobra N.
katiensis), although the neutralizing potency range varied from low
to high. The NKMAV was able to neutralize the venoms of six
Asian cobras (N. kaouthia [Thailand & Malaysia], N. sputatrix, N.
sumatrana, N. siamensis and O. hannah) tested, with efficacy
comparable to that of NPAV, but failed to neutralize the venoms
of B. fasciatus and B. candidus. It is interesting to note that our results
Figure 1. SDS-PAGE of Neuro Polyvalent Snake Antivenom
(NPAV) and Naja kaouthia monovalent antivenom (NKMAV).
Fifteen mL of the respective reconstituted antivenom (3 mg/ml) was
loaded on the middle (NPAV) and right lane (NKMAV). Prestained
molecular weight markers mixture was loaded on the left lane (M,
molecular weight in kDa). The digested heavy chain (H9) and light
chains (L) are indicated by black arrowheads.
doi:10.1371/journal.pntd.0001672.g001
Cross Neutralization of Cobra Venoms
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on the neutralization potentials of NPAV against N. kaouthia, B.
fasciatus, B. candidus and O. hannah venoms are much higher than
stated in the antivenom fact sheet provided, in particular against
O. hannah venom. It should be noted, however, that the definition
of neutralization potential used in the fact sheet has not been
clearly stated.
Figure 2. Elution profiles of (A) Neuro Polyvalent Snake Antivenom (NPAV) and (B) Naja kaouthia monovalent antivenom (NKMAV).
One mg of each sample was applied to Superdex 200 10/300 GL gel column. The arrows identify the peaks. The results of integration of the areas-
under-the-curve are shown in the insert table on the upper left. LMWC stands for low molecular weight components.
doi:10.1371/journal.pntd.0001672.g002
Table 1. In vitro neutralization of lethality of Afro-Asian cobra and krait venoms by NPAV.
Venom i.v. LD50 (mg/g) Challenge dose NPAV
ED50 (mL) ED50 in mg/mL P (mg/mL)
Naja sputatrix 0.90 (0.59–1.36) 5 LD50 111.25 0.93 (0.61–1.41) 0.74
Naja siamensis 0.28 (0.18–0.42) 5 LD50 22.47 1.43 (0.94–2.18) 1.15
Naja sumatrana 0.50 (0.40–0.62) 5 LD50 25.00 2.30 (1.86–2.85) 1.84
Naja kaouthia (Thailand) 0.23 (0.15–0.34) 5 LD50 22.47 1.18 (0.78–1.79) 0.94
Naja kaouthia (Malaysia) 0.89 (0.59–1.35) 5 LD50 150.00 0.68 (0.62–0.75) 0.55
Naja phillipinensis 0.18 (0.12–0.27) 5 LD50 156.57 0.13 (0.11–0.16) 0.10
Naja atra 0.56 (0.37–0.84) 2.5 LD50 56.00 0.86 (0.79–0.94) 0.52
Naja oxiana 1.11 (0.73–1.69) 2.5 LD50 37.50 1.70 (1.56–1.85) 1.01
Naja naja (India 1) 1.80 (1.18–2.73) 2.5 LD50 200.00
*0.52 0.31
Naja naja (India 2) 1.08 (0.71–1.64) 2.5 LD50 156.57 0.40 (0.32–0.49) 0.24
Naja naja (Sri Lanka 1) 1.13 (0.54–2.38) 2.5 LD50 100.00 0.65 (0.52–0.84) 0.39
Naja naja (Sri Lanka 2) 1.08 (0.71–1.64) 5.0 LD50 89.88 1.39 (0.91–2.08) 1.11
Naja haje 0.09 (0.05–1.40) 5.0 LD50 78.29 0.13 (0.11–0.16) 0.10
Naja melanoleuca 0.33 (0.22–0.51) 5.0 LD50 55.63 0.68 (0.44–1.03) 0.54
Naja nigricollis 0.75 (0.69–0.82) 2.5 LD50 55.63 0.78 (0.49–1.18) 0.47
Naja nubiae 0.28 (0.22–0.37) 5.0 LD50 78.29 0.41 (0.34–0.50) 0.33
Naja katiensis 1.20 (0.97–1.45) 2.5 LD50 NE NE NE
Ophiophagus hannah 1.00 (0.81–1.24) 5.0 LD50 11.24 10.23 (6.74–15.54) 8.19
Bungarus fasciatus 1.67 (1.10–2.53) 5.0 LD50 111.25 1.73 (1.14–2.62) 1.38
Bungarus candidus 0.11 (0.07–0.17) 5.0 LD50 13.91 0.91 (0.60–1.38) 0.73
Bungarus flaviceps 0.175 (0.09–0.21) 5.0 LD50 11.24 1.84 (1.21–2.80) 1.47
Bungarus multicintus 0.11 (0.05–0.22) 5.0 LD50 37.50 0.34(0.31–0.37) 0.27
Bungarus caeruleus 0.17 (0.11–0.25) 5.0 LD50 78.29 0.12(0.10–0.15) 0.07
For LD50 and ED50, values in brackets are 95% CI.
2.5 or 5.0 LD50 of venom in 50 mL was premixed with 200 mL of NPAV (Neuro Polyvalent Snake Antivenom) and incubated for 30 min. The mixture was then injected into
mice (n = 4, 20–25 g) and monitored for 48 h. NE: Not effective at maximum volume of antivenom (200 mL) permitted.
*: estimated value, as the maximum volume of antivenom (200 mL) only achieved 50% protection of the animals.
doi:10.1371/journal.pntd.0001672.t001
Cross Neutralization of Cobra Venoms
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In vivo neutralization of lethal effects of some Asian
cobra and krait venoms
Table 3 shows the in vivo neutralization of lethality of four
venoms from Asian cobras and krait (N. sputatrix, N. kaouthia
(Thailand), N.kaouthia (Malaysia) and B. candidus) by NPAV. It is
interesting to note that the i.m.LD50 values determined were
comparable to the corresponding i.v.LD50 values. Our results
showed that NPAV effectively neutralized all four venoms in vivo,
with ED50 comparable to the corresponding ED50 in the in vitro
neutralization assays.
The protective effects of NPAV on the N. sputatrix
venom-induced cardio-respiratory depressant and
neuromuscular blocking effects in the anesthetized rats
Figure 3 shows that NPAV was able to fully protect against the
N. sputatrix venom-induced cardio-respiratory depressant and
neuromuscular blocking effects in the anesthetized rats. The mean
blood pressure (BP), heart rate, respiratory rate and muscle twitch
tension of the control anesthetized rats (‘saline/-’ group) remained
constant for at least 6 hours after the initial stabilization. Following
an intramuscular injection of the venom at 46LD50 dose (6 mg/
kg), however, there was an immediate small decrease (about 20%)
in the BP, which remained constant thereafter for the next 90 min
(Figure 3A). During this period, the heart rate remained essentially
unaffected (Figure 3B). And then the BP and heart rate both began
to fall precipitously from 90 min onward. On the other hand, the
respiratory rate and muscle twitch tension were stable only for the
first 60 min after venom administration. Both these parameters,
however, began to decrease sharply thereafter (Figure 3C and 3D)
and death occurred at 125–130 min after the venom injection.
In a parallel series of experiment conducted to examine the
ability of NPAV to protect against the cardiovascular depressant
and neuromuscular blocking effects of N. sputatrix venom, 1 mL
each of NPAV was administered via the left jugular vein, at 10, 30
and 50 min, respectively, following the i.m. injection of the venom.
The results showed that the administration of the antivenom
effectively reversed the cardio-respiratory depressant and neuro-
muscular blocking effects induced by the N. sputatrix venom. The
heart rate and muscle twitch tension of the antivenom-treated
animals (‘NsV/NPAV’ group) were restored to the same levels as
the ‘saline/-’ control group (P.0.05, not significantly different
between ‘saline/-’ group and ‘NsV/NPAV’ group by one-way
ANOVA), whereas the blood pressure and respiratory rate were
restored to 80% of the control group (P,0.05 between the two
groups) and remained at that level throughout the monitoring
period.
Discussion
Expression of neutralization capabilities of antivenom
In this report, the neutralization capabilities of the antivenoms
are expressed in three different ways: the commonly used median
effective dose ED50 in mL antivenom, ED50 in mg/mL and
potency, P, as defined by Morais et al. [12]. For ED50, expressing
the value in term of mg venom neutralized per mL antivenom is a
more realistic assessment of the neutralization capabilities of the
antivenom than in term mL antivenom or number of mouse LD50,
because the LD50’s of the various cobra venoms differ substan-
tially. For example, expressed in term of mL antivenom, the ED50’s
of NPAV against N. kaouthia (Malaysia) venom and N. philippinensis
Table 2. In vitro and in vivo neutralization of cobra and krait venoms by NPAV and NKMAV.
Venom i.v. LD50 (mg/g) NPAV NKMAV
ED50 (mL) ED50 (mg/mL) P (mg/mL) ED50 (mL) ED50 (mg/mL) P (mg/mL)
Naja sputatrix 0.90 (0.59–1.36) 111.25 0.93 (0.61–1.41) 0.74 111.25 0.93 (0.61–1.41) 0.74
Naja siamensis 0.28 (0.18–0.42) 22.47 1.43 (0.94–2.18) 1.15 22.47 1.43 (0.94–2.18) 1.15
Naja sumatrana 0.50 (0.40–0.62) 25.00 2.30 (1.86–2.85) 1.84 50.00 1.15 (0.93–1.43) 0.92
Naja kaouthia (Thailand) 0.23 (0.15–0.34) 22.47 1.18 (0.78–1.79) 0.94 22.47 1.18 (0.78–1.79) 0.94
Naja kaouthia (Malaysia) 0.89 (0.59–1.35) 150.00 0.68 (0.62–0.75) 0.55 150.00 0.68 (0.62–0.75) 0.55
Ophiophagus hannah 1.0 (0.81–1.24) 11.24 10.23 (6.74–15.54) 8.19 44.94 3.07 (2.80–3.35) 2.46
Abbreviations: NPAV: Neuro Polyvalent Antivenom; NKMAV: Naja kaouthia monovalent antivenom.
Data for NPAV are extracted from Table 1 for comparison purpose. For LD50 and ED50, values in brackets are 95% CI.
Challenge dose for all venoms: 5 LD50.
doi:10.1371/journal.pntd.0001672.t002
Table 3. In vivo neutralization of lethality of some cobra and krait venoms by NPAV.
Species i.m.LD50 (mg/g of mouse) i.v.LD50 (mg/g of mouse)
In vivo Neutralization
(ED50 in mg/mL venom)
In vitro Neutralization
(ED50 in mg/mL venom)
Naja sputatrix 1.41 (1.08–1.85) 0.90 (0.59–1.36) 1.45 (0.96–2.22) 0.93 (0.61–1.41)
Naja kaouthia (Thailand) 0.13 (0.09–0.20) 0.23 (0.15–0.34) 1.59 (1.45–1.89) 1.18 (0.78–1.79)
Naja kaouthia (Malaysia) 1.21 (0.80–1.84) 0.89 (0.59–1.35) 0.88 (0.72–1.09) 0.68 (0.62–0.75)
Bungarus candidus 0.17 (0.11–0.25) 0.11 (0.07–0.17) 0.43 (0.29–0.66) 0.91 (0.60–1.38)
In the in vitro neutralization experiments, 5 LD50 of venom in 50 mL of saline was preincubated with 200 mL of NPAV for 30 min and then injected intravenously into
mice (n = 4, 20–25 g). In the in vivo neutralization experiments, 5 LD50 of venom in 50 mL of saline was injected intramuscularly into mice (n = 4, 20–25 g), and 200 mL of
NPAV was injected to the same mouse intravenously, 10 min later. The animals were monitored for 48 h. For LD50 and ED50, values in brackets are 95% CI.
doi:10.1371/journal.pntd.0001672.t003
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venom are comparable, but when expressed in term of mg/mL,
NPAV was obviously much more effective against N. kaouthia
(Malaysia) venom then against N. philippinensis venom.
Because of the high lethality of certain venoms, a 2.5 LD50
instead of the standard 5 LD50 was used as the challenge dose.
Since the ED50 value of an antivenom is highly dependent on the
challenge dose, ED50 obtained from the two different challenge
doses cannot be compared directly. As such, we also expressed
neutralization capability of the antivenom in terms of P (potency),
which is the mass of venom that is completely neutralized per unit
volume of antivenom, as defined by Morais et al. [12]. Potency
gives a better estimate of the relative efficacy of antivenoms than
comparing ED50 values when different challenge doses were used
in the determination of ED50, as P is theoretically independent of
the amount of challenge doses. Nevertheless, since the relationship
between antivenom neutralizing capability versus venom challenge
dose is not necessarily linear due to the complexity of venom and
antibodies composition, comparing the P values of antivenom
when using different challenge doses does have its limitation.
Comparison of monovalent antivenoms versus
polyvalent antivenoms
The relative merit of monovalent antivenoms versus polyvalent
antivenoms has been the subject of much discussion [14] and there
are some authors who suggested that monovalent antivenoms are
generally more potent than polyvalent antivenoms and less likely
to cause adverse reactions as it may involve administration of a
lower quantity of antivenom IgG that with a polyvalent
antivenom. Several studies have shown, however, that this is not
necessarily true [14,15]. Our results here demonstrated that the
quality and neutralization capabilities of polyvalent antivenom are
not necessary inferior to that of monovalent antivenoms. Here we
compared the protein composition of the N. kaouthia monovalent
antivenom(NKMAV) and Neuro Polyvalent Snake Antivenom
(NPAV), as well as the in vitro neutralization potency of the two
antivenoms against venoms from five common Asiatic cobras and
O. hannah (Table 2). The results show that both antivenoms are
devoid of high molecular weight aggregates, the compounds that
are usually associated with adverse reactions. The protein contents
of the two antivenoms are both relatively low (20.3 mg/mL and
12.5 mg/mL respectively, for NPAV and NKMAV). The
neutralization potencies of NKMAV and NPAV against N.
kaouthia (Thailand) venom (the venom used to raise both
antivenoms) are essentially the same. This, however, is not
surprising since according to the manufacturer, monovalent
antivenoms (including NKMAV) were later added to the purified
polyvalent antivenom to ensure the neutralizing potency of the
NPAV was comparable with the neutralizing potencies of the
respective monovalent antivenoms. What is interesting is that, the
neutralization potencies of both antivenoms against four Asiatic
cobra venoms tested are comparable. NPAV, however, is much
more potent than NKMAV in neutralizing O. hannah venom. This
is to be expected as O. hannah venom was included in the
immunogen mixture used in raising NPAV. These observations
are in accordance with the conclusion drawn by Raweerith and
Ratanabanangkoon [15].
Figure 3. Effects of Neuro Polyvalent Snake Antivenom (NPAV) on the cardio-respiratory depressant and neuromuscular blocking
effects. Changes in percentage (%) of (A) mean blood pressure, (B) heart rate, (C) respiratory rate and (D) muscle twitch tension, upon intramuscular
injection of N. sputatrix venom (6 mg/kg) at 0 min in ‘NsV/-’ group (n = 3; green circle) and ‘NsV/NPAV’ group (n = 3; blue square ); and intramuscular
injection of saline in ‘saline/-’ group (n = 3; red diamond) , which served as the control group. The ‘NsV/NPAV’ group received intravenous injection of
1 mL NPAV each at 10, 30 and 50 min (3 mL in total) post venom injection. *P,0.05 by one-way ANOVA between the ‘NsV/-’ group and ‘NsV/NPAV’
group, within the range indicated by the curly bracket. #P,0.05 by one-way ANOVA between the ‘saline/-’ group and ‘NsV/NPAV’ group, within the
range indicated by the curly bracket. The animals in ‘NsV/-’ group died within 125–130 min upon venom injection. All values are expressed as mean
6 S.D.
doi:10.1371/journal.pntd.0001672.g003
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Neutralization potency of NPAV against venoms of
Malaysian elapids
NPAV was raised using the four common elapid venoms in
Thailand: N. kaouthia (Thailand), O. hannah, B. candidus and B.
fasciatus. Our results showed that the polyvalent antivenom could
effectively neutralize venoms of the same four species that
originated from Malaysia. It is interesting that the polyvalent
antivenom could effectively neutralize venom of N. kaouthia from
Malaysia too. According to Wu¨ster and Thorpe [16], the
composition of the venom of Thai N. kaouthia is substantially
different from that of the Malaysian N. kaouthia, the former appears
to be more neurotoxic, while the latter more necrotic. It was
suggested that this difference in the toxin composition may result
in antivenom incompatibility. Our results, however, showed that
while the two N. kaouthia venoms did differ substantially in their
venom i.v. LD50, the polyvalent antivenom that was raised from
Thai N. kaouthia venom (together with other Thai elapid venoms)
could effectively neutralize the venom of Malaysian N. kaouthia,
albeit with a moderately lower ED50. The same cross-neutraliza-
tion potency was also observed with the monovalent N. kaouthia
antivenom.
In addition to the four elapid venoms mentioned, NPAV also
effectively neutralized the venoms of the other Malaysian kraits B.
flaviceps and B. fasciatus, as well as the medically important
Equatorial spitting cobra N. sumatrana. Thus, the results of our in
vitro neutralization studies suggest that NPAV, which is prepared
from Thai elapid venoms, can be useful in the treatment of elapid
envenoming in Malaysia, since the polyvalent antivenom can
effectively neutralize venoms of all medically important elapids in
Malaysia.
Neutralization potencies of NPAV against other Asiatic
cobra venoms
Our results showed that NPAV was effective (P.0.5 mg/mL)
against other Asiatic cobra venoms, including the venoms of the
three Southeast Asian spitting cobras N. siamensis, N. sumatrana and
N. sputatrix, as well as the venoms of the Central Asia cobra N.
oxiana and Chinese cobra, N. atra. Earlier report claimed that
Chinese cobra N. atra venom was poorly neutralized by other
commercial cobra antivenoms [17]. NPAV, however, was only
weakly effective against the venom of N. philippinensis, the highly
neurotoxic (lethal) Philippine cobra. The low neutralization
potency of 0.11 mg/mL would mean that more than 50 vials of
the antivenom may be required for the victim, as the amount of
venom injected during a cobra bite can be more than 50 mg (dry
weight). Indian polyvalent antivenom (raised from N. naja venom)
has also been reported to show poor neutralizing ability against N.
philippinensis venom.
NPAV was only moderately effective against N. naja venoms
from the Indian subcontinent with the exception of one Sri
Lankan N. naja venom sample (mixtures collected from several
adult N. naja). The variation suggests geographical differences in N.
naja venom.
Thus, our results suggest that NPAV is effective (P.0.5 mg/
mL) in neutralizing the venoms of Asiatic cobras from Southeast
Asia (except the Philippines cobra), Central Asia and China, but
only moderately effective against venoms from the cobras from the
Indian subcontinent. These observations can be used as the basis
for the design of a polyvalent antivenom with a broader spectrum
of cross-neutralization. For example, if venoms of N. philippinensis,
N. naja and B caeruleus were added to the immunogen mixture to
raise NPAV, the resulting polyvalent antivenom may well be an
effective Pan-Asian polyvalent cobra and krait antivenoms.
Neutralization potencies of NPAV against African cobra
venoms
Five common African cobra venoms, including venoms from
three spitting cobras (N. nigricollis, N. nubiae and N. katiensis) were
selected for this study. NPAV could neutralize effectively the
venoms from N. melanoleuca, but is moderately effective against that
of the spitting cobras N. nigricollis and N. nubiae, and weakly or not
effective against venom of the highly lethal N. haje and the spitting
cobra N. katiensis. We have not carried out a thorough study of the
neutralization potency of NPAV against African cobra venoms, as
many of the venoms are not available to us. Nevertheless, the
results showed that there are still substantial cross-neutralizations
between major venom toxins of the Asiatic and the African Naja,
despite the fact that the Asian group lies in a more distant branch
from the African group in the phylogenetic dendrogram [18].
Neutralization potency of NPAV against krait venoms
It is interesting to note that the NPAV could effectively
neutralize the venoms of the three Southeast Asian kraits (B.
fasciatus, B. candidus and B. flaviceps), but only moderately or weakly
against the venoms of the other two kraits (B. multicinctus and B.
caeruleus). The results indicate that krait venoms share enough
common antigens among them to enable the NPAV raised against
B. fasciatus and B. candidus to neutralize all 5 krait venoms tested.
However, the low to moderate potency of NPAV against B.
multicinctus and B. caeruleus venoms indicates significant differences
in antigenicity of some of the venom toxins.
In vivo neutralization potency of NPAV versus in vitro
neutralization potency
For all four elapid venoms tested, the i.m LD50 values are
comparable to the i.v. LD50, indicating that the main venom toxins
could diffuse effectively from muscle to circulation, presumably
because these toxins are mainly low molecular weight proteins
(phospholipases A2 and the three-finger toxins). Also, the
neutralization capability (as measured by ED50) of NPAV in the
in vivo assay is comparable to that of in vitro assay, suggesting that
neutralization potential of antivenom against elapid snakes
measured by the usual in vitro neutralization assay does provide a
good indication of its effectiveness in the in vivo situation.
The protective effects of NPAV against cardiovascular
depressant and neuromuscular blocking effects of N.
sputatrix venom in anesthetised rats
To further examine the in vivo neutralization capability of the
NPAV, we examined its ability to protect against N. sputatrix cobra
venom-induced cardio-respiratory depressant and neuromuscular
blocking effects in anesthetised rats. The antivenom (3 mL in total)
was administered in 3 separate injections to minimize disturbing
the cardio-respiratory parameters. It is well established that the
major lethal toxins of N. sputatrix venom consist of polypeptide
neurotoxins, polypeptide cardiotoxins and phospholipases A2 [19].
The venom-induced cardio-respiratory depressant effect was likely
due to the combined actions of polypeptide cardiotoxins and
phospholipases A2 whereas the neuromuscular blocking effect was
likely due mainly to the action of the venom polypeptide
neurotoxins, although venom phospholipases A2 may also play a
role. Thus, the ability of NPAV to effectively reverse the N. sputatrix
venom-induced cardio-respiratory depressant and neuromuscular
blocking effects in the rats demonstrated that the antivenom did
contain specific antibodies that could effectively neutralize the
major lethal toxins of N. sputatrix venom.
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Conclusions
In conclusion, the in vitro and in vivo neutralization studies
indicated that Neuro Polyvalent Snake Antivenom (NPAV)
effectively neutralized venoms from many Southeast Asian Naja,
Bungarus and Ophiophagus hannah but less effective against the
venoms of Naja from the India subcontinent and Africa, as well as
the Asiatic N. philippinensis. This cross-neutralization information
can be used as the basis for the design of broader-spectrum
polyvalent cobra antivenom. The abilities of NPAV to protect
against N. sputatrix venom-induced cardio-respiratory depressant
and neuromuscular blocking effects confirmed that the antivenom
effectively neutralized the major lethal toxins of Naja venoms. The
antivenom may find potential application in the treatment of
elapid bites in Southeast Asia, especially Malaysia, a neighboring
nation of Thailand. Nevertheless, the applicability of NPAV in the
treatment of cobra and krait envenomations in Southeast Asia
needs to be confirmed by clinical trials, as it is known that
antivenom that has been proved effective in murine model is not
necessarily effective in treating human victims [20].
Acknowledgments
The authors are grateful to Idaman Pharma for assisting in the import of
the antivenoms, and to Queen Saovabha Memorial Institute for supplying
the antivenoms.
Author Contributions
Conceived and designed the experiments: NHT SYF SMS. Performed the
experiments: PKL. Analyzed the data: PKL NHT SYF SMS. Contributed
reagents/materials/analysis tools: NHT KS VS. Wrote the paper: PKL
NHT. Expert comments and advise on antivenoms: KS VS. Edited the
manuscript: PKL SMS SYF KS VS NHT.
References
1. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK,
Pathmeswaran A, et al. (2008) The global burden of snakebite: A literature
analysis and modelling based on regional estimates of envenoming and deaths.
PLoS Med 5: e218.
2. WHO (2010) Guidelines for the prevention and clinical management of
snakebite in Africa. Brazzaville: WHO Regional Office for Africa.
3. Warrell DA (1995) Clinical toxicology of snakebite in Asia. In: Meier J, White J,
eds. Handbook of clinical toxicology of animal venoms and poisons. Florida:
CRC Press. pp 493–594.
4. O’shea M (2005) Venomous Snakes of the World. New Jersey: Princeton
University Press.
5. Chippaux JP (2006) Snake venoms and envenomations. Florida: Krieger
Publishing Company.
6. Warrell DA (2010) Guidelines for the management of snake-bite. WHO. 87 p.
7. Williams D (2011) Global Snake Bite Initiative News. International Society on
Toxinology Newsletter. 59 p.
8. Howard-Jones N (1985) A CIOMS ethical code for animal experimentation.
WHO Chron 39: 51–56.
9. Bradford MM (1976) Rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem 72: 248–254.
10. Studier FW (1973) Analysis of bacteriophage T7 early RNAs and proteins on
slab gels. J Mol Biol 79: 237–248.
11. Ramos-Cerrillo B, de Roodt AR, Chippaux J-P, Olguı´n L, Casasola A, et al.
(2008) Characterization of a new polyvalent antivenom (AntivipmynH Africa)
against African vipers and elapids. Toxicon 52: 881–888.
12. Morais V, Ifran S, Berasain P, Massaldi H (2010) Antivenoms: potency or
median effective dose, which to use? Journal of Venomous Animals and Toxins
including Tropical Diseases 16: 191–193.
13. Finney D (1952) Probit Analysis. Cambridge: Cambridge University Press.
14. Chippaux JP (2010) Guidelines for the production, control and regulation of
snake antivenom immunoglobulins. Biol Aujourdhui 204: 87–91.
15. Raweerith R, Ratanabanangkoon K (2005) Immunochemical and biochemical
comparisons of equine monovalent and polyvalent snake antivenoms. Toxicon
45: 369–375.
16. Wu¨ster W, Thorpe RS (1991) Asiatic cobras: systematics and snakebite.
Experientia 47: 205–209.
17. Minton SA, Jr. (1967) Paraspecific protection by elapid and sea snake antivenins.
Toxicon 5: 47–55.
18. Wu¨ster W, Crookes S, Ineich I, Mane´ Y, Pook CE, et al. (2007) The phylogeny
of cobras inferred from mitochondrial DNA sequences: Evolution of venom
spitting and the phylogeography of the African spitting cobras (Serpentes:
Elapidae: Naja nigricollis complex). Molecular Phylogenetics and Evolution 45:
437–453.
19. Tan NH, Armugam A (1990) In vivo interactions between neurotoxin,
cardiotoxin and phospholipases A2 isolated from Malayan cobra (Naja naja
sputatrix) venom. Toxicon 28: 1193–1198.
20. Warrell DA, Warrell MJ, Edgar W, Prentice CR, Mathison J (1980) Comparison
of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper
(Echis carinatus). Br Med J 280: 607–609.
Cross Neutralization of Cobra Venoms
www.plosntds.org 8 June 2012 | Volume 6 | Issue 6 | e1672
